Get the Stockscreener App
4.02
2.55%
0.10
After Hours:
4.02
Adc Therapeutics Sa stock is traded at $4.02, with a volume of 463.62K.
It is up +2.55% in the last 24 hours and up +5.24% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
See More
Previous Close:
$3.92
Open:
$3.92
24h Volume:
463.62K
Relative Volume:
0.45
Market Cap:
$497.99M
Revenue:
$69.56M
Net Income/Loss:
$-240.05M
P/E Ratio:
-1.3627
EPS:
-2.95
Net Cash Flow:
$-121.90M
1W Performance:
+2.81%
1M Performance:
+5.24%
6M Performance:
+36.73%
1Y Performance:
+171.62%
1-Day Range:
$3.845
$4.02
1-Week Range:
$3.66
$4.195
52-Week Range:
$1.05
$4.80
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Compare ADCT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
4.02 | 485.60M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
Analysts Set ADC Therapeutics SA (NYSE:ADCT) Price Target at $7.50 - Defense World
Bond Watch: Is ADC Therapeutics SA a stock for growth or value investorsGDP Growth & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
ADC Therapeutics SA (NYSE:ADCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.5%Here's Why - MarketBeat
ADC Therapeutics (NYSE:ADCT) Trading Down 4.5%Here's What Happened - MarketBeat
ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.5% – Here’s Why - Defense World
Little Excitement Around ADC Therapeutics SA's (NYSE:ADCT) Revenues - 富途牛牛
ADC Therapeutics SA's (NYSE:ADCT) Price Is Right But Growth Is Lacking - simplywall.st
Update On ADCs: Sales, Deals, Targets And Approvals - Citeline News & Insights
ADC Therapeutics Grants Stock Options to New Employees - Intellectia AI
ADC Therapeutics (ADCT) upgraded to buy: Here's why - MSN
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - Weekly Voice
Growth Review: Can ADC Therapeutics SA continue delivering strong returns2025 Major Catalysts & Technical Pattern Recognition Alerts - baoquankhu1.vn
Has ADC Therapeutics (ADCT) outpaced other medical stocks this year? - MSN
Is ADC Therapeutics SA stock a good dividend stockNew Guidance & High Accuracy Swing Entry Alerts - mfd.ru
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium - marketscreener.com
Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Can ADC Therapeutics SA expand its profit marginsTrade Entry Report & Long-Term Growth Stock Strategies - mfd.ru
Does ADC Therapeutics SA align with a passive investing strategyJuly 2025 Institutional & Capital Efficient Trading Techniques - mfd.ru
Will ADC Therapeutics SA benefit from sector rotation2025 Market Overview & Long-Term Investment Growth Plans - mfd.ru
Moving Averages: Why is ADC Therapeutics SA stock going upStock Surge & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Risk Off: Is ADC Therapeutics SA stock showing strong momentumPortfolio Gains Report & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Weekly Trades: Can ADC Therapeutics SA continue delivering strong returnsLayoff News & Verified Entry Point Detection - mfd.ru
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SAADCT - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SAADCT - PR Newswire
ADC Therapeutics Faces Securities Fraud Investigation, Stock Drops 14.13% - intellectia.ai
Breakouts Watch: Will ADC Therapeutics SA benefit from sector rotationWeekly Stock Report & Growth Oriented Trade Recommendations - baoquankhu1.vn
Insider Trends: Can ADC Therapeutics SA disrupt its industryQuarterly Portfolio Report & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Is ADC Therapeutics SA stock attractive for retirement portfoliosWeekly Gains Report & Real-Time Volume Surge Alerts - bollywoodhelpline.com
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Drops By 47.2% - MarketBeat
ADCT: Zynlonta's pivotal trials aim to transform its market reach and drive major growth from 2027 - TradingView
ADC Therapeutics SA (NYSE:ADCT) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? - sharewise.com
Bull Bear: Why ADC Therapeutics SA stock could benefit from AI revolution2025 Risk Factors & Weekly High Momentum Picks - Bộ Nội Vụ
ADC Therapeutics posts preliminary 2025 revenue of about $73M - MSN
ADC Therapeutics outlines ZYNLONTA-focused growth and financing strategy - TipRanks
How geopolitical tensions affect ADC Therapeutics SA stock2025 Sector Review & Technical Buy Zone Confirmations - Улправда
Can ADC Therapeutics SA Common Shares stock sustain margin levelsCEO Change & Low Drawdown Trading Techniques - ulpravda.ru
Is ADC Therapeutics SA Common Shares stock testing key supportQuarterly Market Review & Free High Accuracy Swing Entry Alerts - Улправда
ADC Therapeutics Announces Preliminary 2025 Financial Results and Outlook - The Globe and Mail
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Sahm
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Ye - GuruFocus
Can ADC Therapeutics SA stock rebound after recent weakness2025 Winners & Losers & Free Reliable Trade Execution Plans - Улправда
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates - PR Newswire
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
ADC Therapeutics SA Common Shares (NY: ADCT - markets.financialcontent.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC ... - Bluefield Daily Telegraph
Will ADC Therapeutics SA stock outperform international peers2026 world cup usa national team round of 32 top scorers high defensive line tactical prediction guide - ulpravda.ru
ADCT stock touches 52-week low at $1.42 amid market challenges - MSN
ADC Therapeutics Announces New Employee Inducement Grant - 富途牛牛
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):